Abstract:Introduction Hospitalized tobacco users with mental illnesses (MI) may face several barriers to stopping smoking. However, motivational factors that affect the intention to engage in tobacco treatment have been shown to predict actual engagement. Aim To use the Theory of Planned Behavior to assess intentions to and prior experiences of engaging in evidence-based tobacco treatment among hospitalized individuals with MI. Method A cross-sectional survey was conducted among 115 patients in a state psychiatric hosp… Show more
“…To verify tobacco use status, participants were assessed using an expired carbon monoxide (expired CO) monitor with a level greater than or equal to 6 parts per milliliter (ppm) indicating current smoking (Deveci et al., 2004). The only exclusion criterion was impaired consent capacity, assessed using a 10‐item Consent Confirmation Questionnaire (CCQ; Okoli et al., 2018). The CCQ is based on true versus false responses that assessed an individual's capacity to understand the procedures and rights as a participant in the study.…”
Tobacco use is a leading cause of disease in people living with mental illnesses (MI). In the U.S., approximately 25% of adults have at least one MI or substance use disorder and these individuals consume nearly 40% of all cigarettes smoked (Prochaska et al., 2017). In fact, tobacco-related death is higher in those with co-occurring MI and substance use disorders as compared to the general population (46.8% vs. 30.7%; Bandiera et al., 2015). Furthermore, on average, individuals with MIs have their life expectancy shortened by 25 years compared to the general population, which, in part, is attributed to tobacco use (Bandiera
“…To verify tobacco use status, participants were assessed using an expired carbon monoxide (expired CO) monitor with a level greater than or equal to 6 parts per milliliter (ppm) indicating current smoking (Deveci et al., 2004). The only exclusion criterion was impaired consent capacity, assessed using a 10‐item Consent Confirmation Questionnaire (CCQ; Okoli et al., 2018). The CCQ is based on true versus false responses that assessed an individual's capacity to understand the procedures and rights as a participant in the study.…”
Tobacco use is a leading cause of disease in people living with mental illnesses (MI). In the U.S., approximately 25% of adults have at least one MI or substance use disorder and these individuals consume nearly 40% of all cigarettes smoked (Prochaska et al., 2017). In fact, tobacco-related death is higher in those with co-occurring MI and substance use disorders as compared to the general population (46.8% vs. 30.7%; Bandiera et al., 2015). Furthermore, on average, individuals with MIs have their life expectancy shortened by 25 years compared to the general population, which, in part, is attributed to tobacco use (Bandiera
“…Individuals with anxiety disorders (ADs) smoke tobacco at rates 2-3 fold higher than those without mental health conditions (Cougle, Zvolensky, Fitch, & Sachs-Ericsson, 2010;Lasser et al, 2000;McCabe et al, 2004). Like other smokers with mental health conditions (Evins, Cather, & Laffer, 2015), smokers with AD typically smoke more heavily (Kelly, Jensen, & Sofuoglu, 2015a), are more severely nicotine-dependent (Okoli, Otachi, Manuel, & Woods, 2018), and experience earlier and more severe nicotine-withdrawal symptoms (Piper, Cook, Schlam, Jorenby, & Baker, 2011) than smokers without mental health conditions, making quitting smoking more challenging (Kelly et al, 2015b). Despite this high rate of co-occurrence and greater difficulty quitting, relatively few randomized controlled trials (RCTs) have evaluated the safety and efficacy of the front-line smoking cessation pharmacotherapies in smokers with AD.…”
Background
Smoking rates are high in adults with anxiety disorders (ADs), yet little is known about the safety and efficacy of smoking‐cessation pharmacotherapies in this group.
Methods
Post hoc analyses in 712 smokers with AD (posttraumatic stress disorder [PTSD], n = 192; generalized anxiety disorder [GAD], n = 243; panic disorder [PD], n = 277) and in a nonpsychiatric cohort (NPC; n = 4,028). Participants were randomly assigned to varenicline, bupropion, nicotine‐replacement therapy (NRT), or placebo plus weekly smoking‐cessation counseling for 12 weeks, with 12 weeks follow‐up. General linear models were used to test the effects of treatment group, cohort, and their interaction on neuropsychiatric adverse events (NPSAEs), and continuous abstinence weeks 9–12 (treatment) and 9–24 (follow‐up).
Results
NPSAE incidence for PTSD (6.9%), GAD (5.4%), and PD (6.2%) was higher versus NPC (2.1%), regardless of treatment. Across all treatments, smokers with PTSD (odds ratio [OR] = 0.58), GAD (OR = 0.72), and PD (OR = 0.53) had lower continuous abstinence rates weeks 9–12 (CAR9–12) versus NPC. Varenicline demonstrated superior efficacy to placebo in smokers with GAD and PD, respectively (OR = 4.53; 95% confidence interval [CI] = 1.20–17.10; and OR = 8.49; 95% CI = 1.57–45.78); NRT was superior to placebo in smokers with PD (OR = 7.42; 95% CI = 1.37–40.35). While there was no statistically significant effect of any treatment on CAR9–12 for smokers with PTSD, varenicline improved 7‐day point prevalence abstinence at end of treatment in this subcohort.
Conclusion
Individuals with ADs were more likely than those without psychiatric illness to experience moderate to severe NPSAEs during smoking‐cessation attempts, regardless of treatment. While the study was not powered to evaluate abstinence outcomes with these subgroups of smokers with ADs, varenicline provided significant benefit for cessation in those with GAD and PD, while NRT provided significant benefit for those with PD.
“…De fato, estudam corroboram estes dados indicando prevalência elevada de tabagismo entre indivíduos internados em instituições psiquiátricas (Okoli et al, 2018).…”
Section: Indivíduos Internadosunclassified
“…Fatores culturais associados aos contextos de internação pioram estas estatísticas, pois a maioria das instituições psiquiátricas ainda permite o consumo do cigarro, que é usado como reforço de comportamentos adequados ou para favorecer a aderência ao tratamento (Flitter et al, 2019). Por outro lado, a proibição do fumo em instituições pode levar à redução de prejuízos associados à saúde, para ambos os fumantes e os não-fumantes (Prochaska, 2011;Flitter et al, 2019;Okoli;Seng, 2019). Com base em princípios de promoção de saúde, a situação de hospitalização deveria oferecer ao fumante acesso restrito ao cigarro, a oportunidade de motivar-se para abandonar o consumo e auxílio para isso (Srivastava et al, 2019).…”
Section: Indivíduos Internadosunclassified
“…A autora expõe de forma detalhada os contrapontos a estes argumentos e vários outros estudos expostos aqui confirmam o aspecto não científico dos mitos citados. Autores enfatizam a importância de conceber a internação como uma oportunidade para intervir sobre o comportamento de fumar e oferecer auxílio medicamentoso de forma monitorada para esta finalidade (Prochaska, 2011;Okoli et al, 2018;Okoli;Seng, 2019;Srivastava et al, 2019)…”
Ao meu orientador, Prof. Dr. João Maurício Castaldelli-Maia, pela confiança, pelo acolhimento, pelos valiosos ensinamentos e por estimular o desenvolvimento da minha autonomia enquanto pesquisadora durante todo esse percurso juntos.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.